Organovo Announces Commercial Release of the exVive3D™ Human Liver Tissue

SAN DIEGO, Nov. 18, 2014  -- Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, today announced the full commercial release of the exVive3DTM Human Liver Tissue for preclinical drug discovery testing.  Initially, clients will be able to access the technology through Organovo's contract research services program. This model is intended to provide human-specific data to aid in the prediction of liver tissue toxicity or ADME outcomes in later stage preclinical drug discovery programs.

Published: 18 November 2014
Written by Editor
AMEX   Project Update  
Read more: Organovo Holdings Inc ( ONVO )

Hamilton Thorne Comments on Unusual Market Activity

BEVERLY, MA and TORONTO, ON--( Nov 17, 2014) - Hamilton Thorne Ltd. (TSX VENTURE: HTL), a leading provider of precision laser devices and advanced image analysis systems for living cell applications in the fertility, stem cell and developmental biology research markets, today reported that, in view of the unusual market activity in the common shares of the Company, the Investment Industry Regulatory Organization of Canada (IIROC) has contacted the Company in accordance with its usual practice. While it ordinarily does not comment on market activity or market rumors, the Company confirmed that it is not aware of any material corporate developments that could account for the unusual trading activity.

Published: 17 November 2014
Written by Editor
TSXV  
Read more: Hamilton Thorne Ltd ( HTL )

Abiomed Announces Second Quarter Fiscal 2015 Revenue of $51.9 Million, Up 17% Over Prior Year

Abiomed on Track for Impella 2.5 and Impella RP FDA Approvals by February/March 2015

DANVERS, Mass., Oct. 30, 2014 -- Abiomed, Inc. (ABMD), a leading provider of breakthrough heart support technologies, today reports second quarter fiscal 2015 revenue of $51.9 million, an increase of 17% compared to revenue of $44.3 million for the same period of fiscal 2014. Second quarter fiscal 2015 GAAP net income was $3.8 million or $0.09 per diluted share, compared to GAAP net income of $1.1 million or $0.03 per diluted share for the prior year period.

Published: 30 October 2014
Written by Editor
Nasdaq   Financial Results   Up on News  
Read more: Abiomed Inc ( ABMD )

Wright Medical Group, Inc. and Tornier N.V. Agree to Merge Creating Premier High-Growth Extremities-Biologics Company

Combination Will Offer Comprehensive Upper and Lower Extremity Product Portfolio and Broad Global Reach
Further Accelerates Growth Opportunities in Three of the Fastest Growing Areas in Orthopaedics
Adds Significant Scale and Scope to Provide Accelerated Path to Profitability and Stronger Financial Profile
Wright Receives Approvable Letter from FDA for Augment® Bone Graft
Wright and Tornier Management to Host Joint Conference Call Today at 4:30 p.m. Central Time

MEMPHIS, Tenn. & AMSTERDAM--- Wright Medical Group, Inc. (WMGI) and Tornier N.V. (TRNX) announced today that they have entered into a definitive merger agreement under which Wright and Tornier will combine in an all stock transaction with a combined equity value of approximately $3.3 billion.

Published: 28 October 2014
Written by Editor
Nasdaq   M & A   Up on News  
Read more: Wright Medical Group Inc ( WMGI )

Alpha Pro Tech, LTD. Announces Financial Results for the Third Quarter Ended September 30, 2014

Record Quarterly Building Supply Segment Sales of $8.5 Million
Income from Operations Increased 15.6% for the Third Quarter and Increased 32.2% Year to Date

  • Net sales increased 4.1% to $13.2 million for the quarter ended September 30, 2014, compared to $12.7 million for the quarter ended September 30, 2013, and increased 6.4% to $35.4 million for the nine-month period ended September 30, 2014 from $33.3 million for the comparable nine-month period of 2013.

Published: 24 October 2014
Written by Editor
AMEX   Financial Results   Up on News  
Read more: Alpha Pro Tech Ltd ( APT )
  1. TSO3 Inc ( TOS )
  2. Theralase Technologies Inc ( TLT )
  3. Unilife Corporation ( UNIS )
  4. IMRIS Inc ( IM / IMRS )
  5. Misonix Inc ( MSON )